TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Suicidal Ideation Through Insomnia Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons 18-65 years of age~* Persons with confirmed DSM-IV diagnosis of MDE by SCID~* Persons with Research Diagnostic Criteria diagnosis of insomnia~* Persons free of all psychotropic medications for one week before baseline assessment, except that prior FLX treatment will require 4 weeks of abstinence, and MAOIs will require 2 weeks of abstinence.~* Persons with Scale for Suicide Ideation (SSI) scores \>2~* Persons with Hamilton Rating Scale for Depression (HRSD24) score \>20~* Persons with Mini Mental State Exam (MMSE) score \>24~* Persons with Insomnia Severity Index (ISI) score \> 7~* Persons with habitual sleep latency \> or = 30 minutes or wake time in the middle of the night of \> or = 30 minutes, and sleep efficiency \< 85%~Exclusion Criteria:~* Non-English speaking, reading, writing persons~* Persons who pose imminent danger to self or others~* Persons with severe suicidal ideation (C-SSRS Suicidal Ideation Score \>3)~* Persons with clinical diagnosis of dementia~* Persons with active or past diagnosis of alcohol or substance abuse, bipolar disorder, schizophrenia per the SCID~* Persons who screen positive for moderate-severe sleep apnea (AHI \>10) or a prior sleep laboratory-confirmed diagnosis of a primary sleep disorder, such as sleep apnea or periodic limb movement disorder.~* Persons with BMI \> 50~* Persons with a self-reported history of napping \> 2 times per week (as these are associated with sleep apnea and periodic limb movement disorder in depressed insomniacs)~* Persons who might be harmed by exposure to hypnotics, including pregnant women and patients with respiratory conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zolpidem-CR (Type: ACTIVE_COMPARATOR): Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-Hodgkin's lymphoma~* CD20+ disease~* Failed at least 1 prior standard systemic therapy~* Persistent lymphoma by physical examination, radiographic studies, bone marrow evaluations, flow cytometry, or polymerase chain reaction~* Tumor burden less than 500 cc by computed tomography or MRI~  * No splenomegaly~* Autologous hematopoietic stem cells or bone marrow harvested and cryopreserved~  * No circulating lymphoma cells by morphology or flow cytometry at or near the time of peripheral blood stem cell (PBSC) collection if unpurged PBSCs are to be used~ * 10% or less marrow involvement by flow cytometry or morphology if purged bone marrow is to be used~* No CNS lymphoma~* No chronic lymphocytic leukemia or small lymphocytic lymphoma/well-differentiated lymphocytic lymphoma~PATIENT CHARACTERISTICS:~Age~* 60 to 80~Performance status~* SWOG 0-1~Life expectancy~* More than 60 days~Hematopoietic~* See Disease Characteristics~Hepatic~* Bilirubin less than 1.5 mg/dL~Renal~* Creatinine less than 2.0 mg/dL~Cardiovascular~* No active coronary artery disease~Pulmonary~* FEV_1 at least 70% of expected~* Vital capacity at least 70% of expected~Other~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* Able to perform self-care during radiation isolation~* No major organ dysfunction~* No major infection~* No circulating anti-mouse antibody~* No other serious medical condition considered to represent contraindications to bone marrow transplantation~* No competing causes of death that would predict life span to be less than 10 additional years~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior bone marrow or stem cell transplantation~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy greater than 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, or more than 25% of red marrow)~Surgery~* Not specified~Other~* More than 30 days since prior systemic antilymphoma therapy

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Type 1 diabetes for ≥ 5 years~2. On their current insulin regimen for ≥ 3 months prior to study entry~3. Screening HbA1c result ≤ 7.5% (58 mmol/mol)~4. Reports self testing of blood glucose levels on a regular basis equivalent to a minimum of 3 times daily for at least 2 months prior to study entry~5. In the investigator's opinion the subject is considered technically capable of using the Abbott Sensor Based Glucose Monitoring System~6. Aged 18 years or over.~Exclusion Criteria:~1. Subject has been diagnosed with hypoglycaemic unawareness (i.e. subject has a diagnosis of impaired awareness of hypoglycaemia recorded in their medical notes OR in the investigator's opinion the subject currently experiences less than minimal warning symptoms for impending hypoglycaemia)~2. Subject is currently prescribed animal insulin~3. Subject is currently prescribed oral steroid therapy or is likely to require oral steroid therapy for any acute or chronic condition during the study~4. Has known allergy to medical grade adhesives~5. Currently participating in another device or drug study that could affect glucose measurements or glucose management~6. Currently using a Continuous Glucose Monitoring (CGM) device or has used one within the previous 4 months~7. Currently using Sensor augmented pump therapy~8. Is planning to use a CGM device at any time during the study~9. A female subject who is pregnant or planning to become pregnant within the study duration~10. A breast feeding mother~11. Currently receiving dialysis treatment or planning to receive dialysis during the study~12. Has a pacemaker~13. Has experienced an acute myocardial infarction within previous 6 months~14. Has a concomitant disease or condition that may compromise subject safety including; unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical condition~15. Has experienced an episode of confirmed or suspected diabetic ketoacidosis (DKA) in the previous 6 months~16. In the investigator's opinion, the subject is considered unsuitable for inclusion in the study for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensor Based Glucose Monitoring System (Type: EXPERIMENTAL): Standard sensing system use for 6 months.
- Standard Blood Glucose Monitoring (Type: ACTIVE_COMPARATOR): Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~(i) Aged between 18-30 years to reduce the confounding effects of lens aging on the transmission of light to the retina;~(ii) Non-smoking for at least 6 months;~(iii) Healthy (no medical, psychiatric or sleep disorders);~(iv) No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, urine chemistry and ECG;~(v) Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative urine pregnancy test;~(vi) Body mass index of \> 18 or \< 30 kg/m2;~(vii) No drugs or medication likely to affect sleep or alertness, as determined by the investigators;~(viii) Habitual caffeine consumption \< 300mg per day on average;~(ix) Habitual alcohol consumption \< 10 alcoholic units per week on average.~Exclusion Criteria:~(i) History of alcohol or substance abuse;~(ii) Positive result on drugs of abuse screening;~(iii) Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;~(iv) Psychiatric disorder;~(v) Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;~(vi) Visual disorder, including but not limited to color blindness, or family history of glaucoma;~(vii) History of intolerance or hypersensitivity to melatonin or melatonin agonists;~(viii) Pregnancy or lactation;~(ix) Shift work;~(x) Transmeridian travel (2 or more time zones) in past 2 months;~(xi) Any other reason as determined by the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Compact Fluorescent Light 90 lux (Type: ACTIVE_COMPARATOR): 90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
- Blue-depleted LED light 90 lux (Type: EXPERIMENTAL): 90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
- Compact Fluorescent Light 50 lux (Type: ACTIVE_COMPARATOR): 50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
- Blue-depleted LED light 50 lux (Type: EXPERIMENTAL): 50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Health Economic Evaluation of Remote Follow up for Implantable Cardioverter Defibrillator (ICD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients already implanted with ICD~* Patients able to be followed in the same centre during all the study~* Patients with age \> 18~* Patients able to understand and to answer to EuroQoL Group 5-Dimension (EQ-5D) Questionnaire~Exclusion Criteria:~* Patients pregnant~* Patients unable to connect Merlin@home transmitters with Website Merlin.net (i.e.without telephonic analogic line or Global System for Mobile Communication (GSM)/Universal Mode Telecommunication System (UMTS) connection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Follow Up (Type: None): ICD patients followed through periodic in-hospital visits
- Remote Follow Up (Type: None): ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female subjects participating in FMSU2013-004A protocol with known clinical status~Exclusion Criteria:~* Female subjects that did not have known clinical status in FMSU2013-004A

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DBT plus S-View (Type: None): Breast images utilizing DBT plus S-View
- FFDM alone (Type: None): Breast images using FFDM alone only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Responses of Myocardial Ischemia to Escitalopram Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 or greater, less than 90~* Stable ischemic heart disease~Exclusion Criteria:~* Recent myocardial infarction, coronary artery bypass graft surgery, or other revascularization procedures (less than 3 months ago)~* Left ventricular ejection fraction(LVEF) \< 15% measured by echocardiography, radionuclide ventriculography (RNV), or cardiac catheterization~* Life threatening arrhythmia or arrhythmia interrupting the interpretation of ischemia~* Unable to withdraw from anti-anginal medications during ischemic assessment phase~* Unable to perform exercise testing~* Pregnancy~* Current or previous history of bipolar disorder, cyclothymia, schizophrenia, schizoaffective or schizophreniform disorder, or other psychotic disorders~* Active suicidal ideation~* Current substance abuse or history of substance abuse in the previous 6 months~* Significant cardiac, pulmonary, metabolic, renal, hepatic disease, or malignancy, interfering with patient's participation in this study~* Seizure (history and/or present) with/without treatment~* Currently taking antidepressants that cannot be discontinued

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Escitalopram treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are either Male or Female at least 18 years of age~* are scheduled for radical cystectomy~* are scheduled to receive postoperative pain management with intravenous participant-controlled opioid analgesics~Exclusion Criteria:~* are scheduled for a partial cystectomy~* have taken more than 3 doses of opioids (oral or parenteral) within 7 days before the day of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvimopan (Type: EXPERIMENTAL): 12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment
- Placebo (Type: PLACEBO_COMPARATOR): 300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* 18 years of age or greater~* must be scheduled for an autologous or allogeneic bone marrow or peripheral stem cell transplant~* Eastern Cooperative Oncology Group(ECOG) performance status \< or = 2~* patients must have signed informed consent~* must be able to swallow tablets and capsules~* must be receiving a cyclophosphamide containing regimen.~Exclusion:~* patient has known sensitivity to aprepitant, ondansetron, or dexamethasone~* patient has received another investigational drug in the past 30 days~* patient has had emesis or requires antiemetic agents in the 48 hours prior to beginning conditioning therapy~* patient has taken neurokinin-1 antagonists for 14 days prior to enrollment~* patient is pregnant, has a positive serum human chorionic gonadotropin(hCg) or is lactating~* patient has serum creatinine level \> or = 2\*ULN~* patient has severe hepatic insufficiency (Child-Pugh score \>9)~* patient drinks \> 5 drinks/day for the last year~* patient with concurrent illness requiring systemic corticosteroid use other than planned dexamethasone during conditioning therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: ACTIVE_COMPARATOR): None
- sugar pill (Type: PLACEBO_COMPARATOR): Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical 5% Imiquimod Cream for Vulvar Paget's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-invasive vulvar Paget's disease, primary or recurrence after earlier surgery;~* Willing and able to comply with the protocol and to provide informed consent in accordance with institutional and regulatory guidelines.~Exclusion Criteria:~* Invasive vulvar Paget's disease;~* Underlying adenocarcinoma;~* Treatment of the vulva with topical 5% imiquimod cream during the last 6 months;~* Participation in a study with another investigational product within 30 days prior to enrolment in this study;~* Hypersensitivity to any component of topical 5% imiquimod cream (methylhydroxybenzoate (E218), propylhydroxybenzoate (E216), cetylalcohol, atearylalcohol);~* Patients with autoimmune disorders;~* Immune compromised patients (e.g. HIV patients, patients with a history of transplantation);~* Insufficient understanding of the Dutch or English language;~* Pregnant women;~* Lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Imiquimod (Type: EXPERIMENTAL): Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients were eligible for this study if they met the American Rheumatism Association classification criteria for RA (9), had a disease duration inferior to one year, suffered from active disease (defined as the presence of a swollen joint count \[SJC\] ≥ 6 \[by the 66 joints count\] and a tender joint count \[TJC\] ≥ 8 \[by the 68 joints count\]) and had not been treated with MTX before.~* Patients were eligible for this study if they met the American Rheumatism Association classification criteria for RA (9), had a disease duration inferior to one year, suffered from active disease (defined as the presence of a swollen joint count \[SJC\] ≥ 6 \[by the 66 joints count\] and a tender joint count \[TJC\] ≥ 8 \[by the 68 joints count\]) and had not been treated with MTX before.~Exclusion Criteria:~* Exclusion criteria included past/current history of tuberculosis, congestive heart disease, past treatment with GC for more than 3 months (and not during the 4 weeks before inclusion), previous treatment with more than 2 DMARDs, MTX, IV MP pulse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Methotrexate
- B (Type: ACTIVE_COMPARATOR): MTX + MP
- C (Type: ACTIVE_COMPARATOR): MTX + IFX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete